이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

제한기 소세포폐암(TIGOS-LS)에서 BMS-986489(Atigotatug + Nivolumab) 대 Durvalumab (TIGOS-LS)

2026년 9월 16일 업데이트: SCRI Development Innovations, LLC

제한 단계 소세포폐암(TIGOS-LS)의 화학방사선요법 후 통합 요법으로 BMS-986489(Atigotatug + Nivolumab 고정 용량 병용)와 Durvalumab에 대한 공개 무작위 연구

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.

The main goals of this study are to:

  • Evaluate the efficacy of BMS-986489 vs durvalumab
  • Evaluate the safety profile of BMS-986489

연구 개요

상태

모집하지 않고 적극적으로

상세 설명

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in participants with limited-stage (LS)-small-cell lung cancer (SCLC). Participants will receive concurrent chemotherapy and radiotherapy according to standard guidelines for treatment of LS-SCLC without progressive disease prior to randomization. Eligible participants will be randomly assigned to receive either BMS-986489 (atigotatug + nivolumab as a fixed-dose combination; Arm A) or durvalumab (Arm B) as consolidation therapy. Atigotatug is a first-in-class, fully human IgG1 antibody being developed for the treatment of SCLC. Atigotatug specifically binds to fuc-GM1 on the tumor cell. Nivolumab is a monoclonal anti-PD-1 antibody. Combining atigotatug with another immunotherapy may provide enhanced antitumor effects.

연구 유형

중재적

등록 (추정된)

250

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alabama
      • Daphne, Alabama, 미국, 36526
        • Southern Cancer Center
    • California
      • Santa Barbara, California, 미국, 93105
        • Sansum Clinic
    • Florida
      • Fort Myers, Florida, 미국, 33901
        • Florida Cancer Specialists - South
      • Miami, Florida, 미국, 33136
        • University of Miami - Sylvester Cancer Center
      • Ocala, Florida, 미국, 34474
        • Ocala Oncology Center
      • Orange City, Florida, 미국, 32763
        • Florida Cancer Specialists - North
      • Palm Bay, Florida, 미국, 32901
        • Cancer Care Centers of Brevard
      • West Palm Beach, Florida, 미국, 33401
        • Florida Cancer Specialists - East
    • Georgia
      • Atlanta, Georgia, 미국, 30309
        • Piedmont Healthcare - Atlanta
    • Illinois
      • Arlington Heights, Illinois, 미국, 60005
        • Illinois Cancer Specialists
      • Peoria, Illinois, 미국, 61615
        • Illinois Cancer Care
    • Indiana
      • Indianapolis, Indiana, 미국, 46202
        • Indiana University Simon Cancer Center
    • Kentucky
      • Corbin, Kentucky, 미국, 40701
        • Baptist Health - Corbin
      • Lexington, Kentucky, 미국, 40503
        • Baptist Health - Lexington
      • Louisville, Kentucky, 미국, 40207
        • Baptist Health - Louisville
    • Minnesota
      • Maple Grove, Minnesota, 미국, 55369
        • Minnesota Oncology Hematology
    • Missouri
      • Columbia, Missouri, 미국, 65201
        • Missouri Cancer Associates
    • New York
      • White Plains, New York, 미국, 10601
        • White Plains Hospital Physician Associates
    • North Carolina
      • Wilson, North Carolina, 미국, 27896
        • Carolina Cancer Research Center
    • Ohio
      • Cincinnati, Ohio, 미국, 45242
        • Oncology Hematology Care
      • Columbus, Ohio, 미국, 43210
        • The Ohio State University - Arthur James Cancer Hospital & Solove Research Institute
      • Columbus, Ohio, 미국, 43219
        • Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center
    • Oregon
      • Eugene, Oregon, 미국, 97401
        • Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center)
    • Tennessee
      • Knoxville, Tennessee, 미국, 37909
        • Tennessee Cancer Specialists
      • Nashville, Tennessee, 미국, 37203
        • SCRI Oncology Partners
    • Texas
      • Amarillo, Texas, 미국, 79124
        • Texas Oncology - West Texas
      • Austin, Texas, 미국, 78705
        • Texas Oncology- Austin
      • Beaumont, Texas, 미국, 77702
        • Texas Oncology - Gulf Coast
      • Dallas, Texas, 미국, 75246
        • Texas Oncology - DFW
      • Denison, Texas, 미국, 75020
        • Texas Oncology - Northeast Texas
      • San Antonio, Texas, 미국, 78240
        • Texas Oncology - San Antonio
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Virginia Cancer Specialists
      • Norfolk, Virginia, 미국, 23502
        • Virginia Oncology Associates
      • Salem, Virginia, 미국, 24153
        • Blue Ridge Cancer Center (Oncology & Hematology Associates of Southwest VA)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • At least 18 years-of-age at the time of signature of the Informed Consent Form (ICF)

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (Appendix A)

  • Histologically or cytologically confirmed pulmonary SCLC, evaluable by RECIST v1.1

  • Limited-stage (LS) disease as determined by positron emission tomography (PET) scan prior to initiation of chemotherapy and radiation therapy

  • Completed concurrent chemotherapy and radiotherapy for LS-SCLC without progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (computed tomography [CT] scan chest/abdomen/pelvis; Appendix B) within 42 days before date of randomization and first dose of study treatment

    • Chemotherapy should consist of a platinum and IV etoposide. Participants who received at least 3 cycles of chemotherapy will be eligible to participate.
    • Radiotherapy should be administered per institutional guidelines
  • Prophylactic cranial irradiation (PCI) may be delivered at the discretion of the Investigator and institutional guidelines. PCI, if applicable, must be conducted after the end of chemoradiotherapy and completed between 14 and 42 days before date of randomization and first dose of study treatment.

  • Adequate hematologic and organ function

  • Willingness to abide by protocol defined contraceptive requirements for the duration of the study.

Exclusion Criteria:

  • Small-cell cancer not pulmonary in origin

  • Large cell neuroendocrine carcinoma

  • ES-SCLC

  • Mixed SCLC and NSCLC histologic features; diagnosis of NSCLC; or EGFR-activating, mutation-positive NSCLC that has transformed to SCLC

  • History of severe hypersensitivity reaction to monoclonal antibodies

  • Known hypersensitivity to any excipients of atigotatug, nivolumab, or durvalumab

  • Grade ≥2 peripheral neuropathy by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0

  • Active, prior, or suspected autoimmune disease, including autoimmune neurologic disorders such as paraneoplastic syndrome involving the CNS, peripheral sensory/motor nerves, or neuromuscular junction. Exceptions to this criterion include:

    • Type 1 diabetes mellitus
    • Hypothyroidism requiring only hormone replacement
    • Skin disorders not requiring systemic treatment
    • Autoimmune conditions not expected to recur during the study
  • Diseases or conditions requiring chronic systemic corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive therapy within 14 days of starting study treatment. Limited-course (<2 weeks' duration) oral steroids (10 mg prednisone or equivalent) are permitted. Bronchodilators, inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.

  • History of solid organ or bone marrow transplantation

  • History of Grade ≥2 pneumonitis (excepting resolved infective pneumonitis)

  • Any of the following cardiac criteria, currently or within the last 3 months:

    • Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting electrocardiograms (ECGs), e.g., complete left bundle branch block, third-degree heart block, atrial fibrillation not rate controlled. Certain conditions may be considered through discussion with the Medical Monitor.
    • Congestive heart failure (New York Heart Association [NYHA] > Grade 2) or classified as Class 3 or 4 by the NYHA Functional Classification (Appendix D)
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, uncontrolled hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval (Appendix E). Certain conditions may be considered through discussion with the Medical Monitor.
    • Participants with a left ventricular ejection fraction <55% or the lower limit of normal of the institutional standard
    • Uncontrolled hypertension, defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management
    • Active coronary artery disease, including unstable or newly diagnosed angina
    • Myocardial infarction
    • History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes)
    • History or current diagnosis of myocarditis
  • As judged by the Investigator, participants with serious or uncontrolled medical disorders

  • Presence of other active invasive cancers. Participants with a previously treated malignancy will be eligible to participate if treatment of that malignancy was completed at least 2 years before date of screening and the participants has no evidence of disease. Exceptions to this criterion include appropriately treated basal cell carcinoma of the skin; in situ carcinoma of uterine cervix; localized prostate cancer that has been definitively treated; or other local tumors considered cured by local treatment.

  • Received sequential chemotherapy and radiotherapy as a definitive treatment for LS-SCLC

  • Treatment with any of the following:

    • Any systemic anticancer chemotherapy, small molecule, biologic, or hormonal agent from a previous treatment regimen or clinical study within 21 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment
    • Wide-field radiotherapy (including therapeutic radioisotopes such as strontium-89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting study treatment or has not recovered from side effects of such therapy
    • Prior systemic treatment for LS-SCLC, with the exception of chemoradiotherapy and PCI
    • Prior treatment with an anti-PD-1, anti-PD-L1, anti-programmed cell death ligand 2 (anti-PD-L2), anti-CD137, anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways
    • Prior treatment with fuc-GM-1 vaccine or targeted agent or similar vaccine targeting ganglioside antigens
    • Current treatment with immunosuppressive medications
    • Live attenuated vaccine within 100 days before first dose of study treatment
  • Major surgery (excluding placement of vascular access) within 4 weeks of date of screening

  • With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment. Note: Participants with chronic Grade 2 toxicities who are asymptomatic or adequately managed with stable medication may be eligible with approval by the Medical Monitor or Principal Investigator.

  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: BMS-986489 (atigotatug + nivolumab)

Participants will receive a fixed dose of BMS-986489 (atigotatug + nivolumab) intravenously each cycle. Cycles will be 28 days. Up to 125 participants will be enrolled into this arm.

BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.

활성 비교기: Durvalumab

Participants will receive standard of care Durvalumab intravenously each cycle. Cycles will be 28 days. Up to 125 participants will be enrolled into this arm.

Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Evaluate the efficacy of BMS-986489 vs durvalumab by Overall Survival (OS).
기간: From date of randomization up to 5 years. Every 8 weeks for participants who stopped treatment before disease progression and before completing 6 months of treatment and every 12 weeks for participants who stopped treatment before disease progression and

Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause.

From date of randomization up to 5 years. Every 8 weeks for participants who stopped treatment before disease progression and before completing 6 months of treatment and every 12 weeks for participants who stopped treatment before disease progression and

2차 결과 측정

결과 측정
측정값 설명
기간
Evaluate the efficacy of BMS-986489 vs durvalumab by Progression Free Survival (PFS).
기간: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

Progression Free Survival (PFS) is defined as the time from start of study treatment to the date of an event, defined as the first documented radiological progression or death due to any cause.

Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.
Evaluate the efficacy of BMS-986489 vs durvalumab Objective Response Rate (ORR).
기간: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

Objective Response Rate (ORR) is defined as the proportion of participants with BOR of CR or PR according to RECIST v1.1.

Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.
Evaluate the efficacy of BMS-986489 vs durvalumab by Clinical Benefit Rate (CBR).
기간: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

Clinical Benefit Rate (CBR) is defined as the proportion of participants with BOR of CR or PR, or participants with SD lasting at least 180 days (i.e., ≥6 months) according to RECIST v1.1.

Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.
Evaluate the efficacy of BMS-986489 vs durvalumab by Disease Control Rate (DCR).
기간: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

Disease Control Rate (DCR) is defined as the proportion of participants with BOR of CR, PR, or SD according to RECIST v1.1

Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.
Evaluate the efficacy of BMS-986489 vs durvalumab by Duration of Response (DoR).
기간: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

Duration of Response (DoR) is defined as the duration from the first documented response (Complete Response (CR), Partial Response (PR), or Stable Disease (SD), according to RECIST v1.1) to the date of first documented disease progression or death.

Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.
Evaluate the efficacy of BMS-986489 vs durvalumab by Time to Progression (TtP).
기간: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

Time to Progression (TtP) is defined as the time from the date of randomization to the date of first documented disease progression, according to RECIST v1.1.

Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.
Evaluate the efficacy of BMS-986489 vs durvalumab by time to development of central nervous system (CNS) metastasis.
기간: Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.

Time to development of central nervous system (CNS) metastasis is defined as the time from the date of randomization to the date of first documented CNS metastasis.

Every 2 cycles (8 weeks) from Cycle 1 Day 1, for the first 6 months, then every 3 cycles (12 weeks) until disease progression or death, up to 3 years. Each cycle is 28 days.
Evaluate the number of participants with adverse events following administration of BMS-986489.
기간: From Cycle 1 Day 1 to 100 days after the last dose of BMS-986489. Each cycle is 28 days.

Adverse Events to be evaluated per CTCAE v5.0 criteria from first dose of BMS-986489 to 100 days after the last dose of BMS-986489.

From Cycle 1 Day 1 to 100 days after the last dose of BMS-986489. Each cycle is 28 days.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: Melissa Johnson, MD, SCRI Development Innovations, LLC

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 3월 11일

기본 완료 (추정된)

2032년 5월 1일

연구 완료 (추정된)

2032년 9월 1일

연구 등록 날짜

최초 제출

2025년 1월 8일

QC 기준을 충족하는 최초 제출

2025년 1월 8일

처음 게시됨 (실제)

2025년 1월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 16일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다